|
1
|
Mammas IN, Greenough A, Theodoridou M and
Spandidos DA: The foundation of the institute of paediatric
virology on the Island of Euboea, Greece (Review). Exp Ther Med.
20(302)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mammas IN and Spandidos DA: The philosophy
of paediatric teaching: An interview with Dr Nikolaos
Myriokefalitakis, former clinical director of the ‘Penteli’
Children's Hospital in Athens (Greece). Exp Ther Med. 16:2799–2802.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mammas IN, Theodoridou M and Spandidos DA:
COVID-19 and paediatric challenges: An interview with professor of
paediatrics Vana Papaevangelou (University of Athens School of
Medicine). Exp Ther Med. 20(296)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
World Health Organization (WHO): WHO
Director-General's opening remarks at the media briefing on
COVID-19-11 March 2020. WHO, Geneva, 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
Accessed December 10, 2020.
|
|
5
|
Coronaviridae Study Group of the
International Committee on Taxonomy of Viruses. The species severe
acute respiratory syndrome-related coronavirus: Classifying
2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536–544.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from
patients with pneumonia in China, 2019. N Engl J Med. 382:727–733.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Arabi YM, Arifi AA, Balkhy HH, Najm H,
Aldawood AS, Ghabashi A, Hawa H, Alothman A, Khaldi A and Al Raiy
B: Clinical course and outcomes of critically ill patients with
Middle East respiratory syndrome coronavirus infection. Ann Intern
Med. 160:389–397. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Rossi GA, Sacco O, Mancino E, Cristiani L
and Midulla F: Differences and similarities between SARS-CoV and
SARS-CoV-2: Spike receptor-binding domain recognition and host cell
infection with support of cellular serine proteases. Infection.
48:665–669. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song
ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al: A new coronavirus
associated with human respiratory disease in China. Nature.
579:265–269. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lai MM, Patton CD and Stohlman SA: Further
characterization of mRNA's of mouse hepatitis virus: Presence of
common 5’-end nucleotides. J Virol. 41:557–565. 1982.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wu HY and Brian DA: Subgenomic messenger
RNA amplification in coronaviruses. Proc Natl Acad Sci USA.
107:12257–12262. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fehr AR and Perlman S: Coronaviruses: An
overview of their replication and pathogenesis. Methods Mol Biol.
1282:1–23. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yan R, Zhang Y, Li Y, Xia L, Guo Y and
Zhou Q: Structural basis for the recognition of SARS-CoV-2 by
full-length human ACE2. Science. 367:1444–1448. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li F, Li W, Farzan M and Harrison SC:
Structure of SARS coronavirus spike receptor-binding domain
complexed with receptor. Science. 309:1864–1868. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA,
Hsieh CL, Abiona O, Graham BS and McLellan JS: Cryo-EM structure of
the 2019-nCoV spike in the prefusion conformation. Science.
367:1260–1263. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Millet JK and Whittaker GR: Host cell
proteases: Critical determinants of coronavirus tropism and
pathogenesis. Virus Res. 202:120–134. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Coutard B, Valle C, de Lamballerie X,
Canard B, Seidah NG and Decroly E: The spike glycoprotein of the
new coronavirus 2019-nCoV contains a furin-like cleavage site
absent in CoV of the same clade. Antiviral Res.
176(104742)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shang J, Wan Y, Luo C, Ye G, Geng Q,
Auerbach A and Li F: Cell entry mechanisms of SARS-CoV-2. Proc Natl
Acad Sci USA. 117:11727–11734. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H,
Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and
epidemiology of 2019 novel coronavirus: Implications for virus
origins and receptor binding. Lancet. 395:565–574. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu X, Chen P, Wang J, Feng J, Zhou H, Li
X, Zhong W and Hao P: Evolution of the novel coronavirus from the
ongoing Wuhan outbreak and modeling of its spike protein for risk
of human transmission. Sci China Life Sci. 63:457–460.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wong YC, Lau SY, Wang To KK, Mok BWY, Li
X, Wang P, Deng S, Woo KF, Du Z, Li C, et al: Natural transmission
of bat-like severe acute respiratory syndrome coronavirus 2 without
proline-arginine-arginine-alanine varinats in coronavirus disease
2019 patients. Clin Infect Dis. 73:e437–e444. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Andersen KG, Rambaut A, Lipkin WI, Holmes
EC and Garry RF: The proximal origin of SARS-CoV-2. Nat Med.
26:450–452. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cheng MH, Zhang S, Porritt RA, Noval Rivas
M, Paschold L, Willscher E, Binder M, Arditi M and Bahar I:
Superantigenic character of an insert unique to SARS-CoV-2 spike
supported by skewed TCR repertoire in patients with
hyperinflammation. Proc Natl Acad Sci USA. 117:25254–25262.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Goh GK, Dunker AK and Uversky VN:
Understanding viral transmission behavior via protein intrinsic
disorder prediction: Coronaviruses. J Pathog.
2012(738590)2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Goh GK, Dunker AK, Foster JA and Uversky
VN: Shell disorder analysis predicts greater resilience of the
SARS-CoV-2 (COVID-19) outside the body and in body fluids. Microb
Pathog. 144(104177)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ding S and Liang TJ: Is SARS-CoV-2 also an
enteric pathogen with potential fecal-oral transmission? A COVID-19
virological and clinical review. Gastroenterology. 159:53–61.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rasmussen SA, Smulian JC, Lednicky JA, Wen
TS and Jamieson DJ: Coronavirus disease 2019 (COVID-19) and
pregnancy: What obstetricians need to know. Am J Obstet Gynecol.
222:415–426. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lu Q and Shi Y: Coronavirus disease
(COVID-19) and neonate: What neonatologist need to know. J Med
Virol. 92:564–567. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lamouroux A, Attie-Bitach T, Martinovic J,
Leruez-Ville M and Ville Y: Evidence for and against vertical
transmission for severe acute respiratory syndrome coronavirus 2.
Am J Obstet Gynecol. 223:91.e1–91.e4. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gengler C, Dubruc E, Favre G, Greub G, de
Leval L and Baud D: SARS-CoV-2 ACE-receptor detection in the
placenta throughout pregnancy. Clin Microbiol Infect. 27:489–490.
2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kotlyar AM, Grechukhina O, Chen A,
Popkhadze S, Grimshaw A, Tal O, Taylor HS and Tal R: Vertical
transmission of coronavirus disease 2019: A systematic review and
meta-analysis. Am J Obstet Gynecol. 224:35–53.e3. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Khalil A, von Dadelszen P, Draycott T,
Ugwumadu A, O’Brien P and Magee L: Change in the incidence of
stillbirth and preterm delivery during the COVID-19 pandemic. JAMA.
324:705–706. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
35
|
Milstone A: Coronavirus in babies and
kids. The Johns Hopkins Hospital. Updated April 24, 2020.
|
|
36
|
Tan X, Huang J, Zhao F, Zhou Y, Li JQ and
Wang XY: Clinical features of children with SARS-CoV-2 infection:
An analysis of 13 cases from Changsha, China. Zhongguo Dang Dai Er
Ke Za Zhi. 22:294–298. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
37
|
Shahabinezhad F, Mosaddeghi P,
Negahdaripour M, Dehghani Z, Farahmandnejad M, Moghadami M, Nezafat
N and Masoompour SM: Therapeutic approaches for COVID-19 based on
the dynamics of interferon-mediated immune responses. Curr Signal
Transduct Ther. 16:269–280. 2021.
|
|
38
|
Cristiani L, Mancino E, Matera L, Nenna R,
Pierangeli A, Scagnolari C and Midulla F: Will children reveal
their secret? The coronavirus dilemma. Eur Respir J.
55(2000749)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Skarstein Kolberg E: ACE2, COVID19 and
serum ACE as a possible biomarker to predict severity of disease. J
Clin Virol. 126(104350)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
de Souza TH, Nadal JA, Nogueira RJN,
Pereira RM and Brandão MB: Clinical manifestations of children with
COVID-19: A systematic review. Pediatr Pulmonol. 55:1892–1899.
2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Recalcati S: Cutaneous manifestations in
COVID-19: A first perspective. J Eur Acad Dermatol Venereol.
34:e212–e213. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Henry BM, de Oliveira MHS, Benoit S,
Plebani M and Lippi G: Hematologic, biochemical and immune
biomarker abnormalities associated with severe illness and
mortality in coronavirus disease 2019 (COVID-19): A meta-analysis.
Clin Chem Lab Med. 58:1021–1028. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li
FB, Lin R, Tang LF, Wang TL, Wang W, et al: Diagnosis and treatment
recommendations for pediatric respiratory infection caused by the
2019 novel coronavirus. World J Pediatr. 16:240–246.
2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lee PI, Hu YL, Chen PY, Huang YC and Hsueh
PR: Are children less susceptible to COVID-19? J Microbiol Immunol
Infect. 53:371–372. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wei M, Yuan J, Liu Y, Fu T, Yu X and Zhang
ZJ: Novel coronavirus infection in hospitalized infants under 1
year of age in China. JAMA. 323:1313–1314. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Choi SH, Kim HW, Kang JM, Kim DH and Cho
EY: Epidemiology and clinical features of coronavirus disease 2019
in children. Clin Exp Pediatr. 63:125–132. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Riphagen S, Gomez X, Gonzalez-Martinez C,
Wilkinson N and Theocharis P: Hyperinflammatory shock in children
during COVID-19 pandemic. Lancet. 395:1607–1608. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Crayne C and Cron RQ: Pediatric macrophage
activation syndrome, recognizing the tip of the Iceberg. Eur J
Rheumatol. 7 (Suppl 1):S1–S8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wang W, Gong F, Zhu W, Fu S and Zhang Q:
Macrophage activation syndrome in Kawasaki disease: More common
than we thought? Semin Arthritis Rheum. 44:405–410. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Belhadjer Z, Méot M, Bajolle F, Khraiche
D, Legendre A, Abakka S, Auriau J, Grimaud M, Oualha M, Beghetti M,
et al: Acute heart failure in multisystem inflammatory syndrome in
children in the context of global SARS-CoV-2 pandemic. Circulation.
142:429–436. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Verdoni L, Mazza A, Gervasoni A, Martelli
L, Ruggeri M, Ciuffreda M, Bonanomi E and D’Antiga L: An outbreak
of severe Kawasaki-like disease at the Italian epicentre of the
SARS-CoV-2 epidemic: An observational cohort study. Lancet.
395:1771–1778. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Feldstein LR, Rose EB, Horwitz SM, Collins
JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM,
Martin AA, et al: Multisystem inflammatory syndrome in U.S.
children and adolescents. N Engl J Med. 383:334–346.
2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Bauchner H: 2020-A year that will be
remembered. JAMA. 324(245)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Antoniou KM, Raghu G, Tzilas V and Bouros
D: Management of patients with interstitial lung disease in the
midst of the COVID-19 pandemic. Respiration. 99:625–627.
2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tzouvelekis A, Karampitsakos T and Bouros
D: The role of hydroxychloroquine in coronavirus disease 2019. A
versatile tool at the service of humanity. Front Med (Lausanne).
7(176)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
RECOVERY Collaborative Group. Horby P,
Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M,
Ustianowski A, Elmahi E, et al: Effect of hydroxychloroquine in
hospitalized patients with Covid-19. N Engl J Med. 383:2030–2040.
2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK,
Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et
al: Remdesivir for the treatment of Covid-19-final report. N Engl J
Med. 383:1813–1826. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
RECOVERY Collaborative Group. Horby P, Lim
WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, et al: Dexamethasone in hospitalized
patients with Covid-19. N Engl J Med. 384:693–704. 2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
WHO Solidarity Trial Consortium. Pan H,
Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool
Karim Q, Alejandria MM, Hernández García C, Kieny MP, et al:
Repurposed antiviral drugs for Covid-19-interim WHO solidarity
trial results. N Engl J Med. 384:497–511. 2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
U.S. National Library of Medicine:
Inpatient Treatment of COVID-19 With Anti-Coronavirus
Immunoglobulin (ITAC). ClinicalTrials.gov: NCT04546581. https://clinicaltrials.gov/ct2/history/NCT04546581.
Accessed December 10, 2020.
|
|
61
|
The Food and Drug Administration (FDA):
Coronavirus treatment acceleration program (CTAP). https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap.
Accessed February 22, 2022.
|
|
62
|
Hippocrates: Epidemics I (Epidemion to
Proton). In: Hippocrates, Apanta 13. Cactus Editions, Athens, 1993
(In Greek).
|
|
63
|
U.S. National Library of Medicine:
ACTIV-5/Big Effect Trial (BET-B) for the Treatment of COVID-19.
ClinicalTrials.gov: NCT04583969. https://clinicaltrials.gov/ct2/history/ct2/history/NCT04583969.
Accessed December 10, 2020.
|
|
64
|
Iacob S and Iacob G: SARS-CoV-2 treatment
approaches: Numerous options, no certainty for a versatile virus.
Front Pharmacol. 11(1224)2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lamb YN: Remdesivir: First approval.
Drugs. 80:1355–1363. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Stevens B: The story of remdesivir. New
York Times, New York, NY, 2020. https://www.nytimes.com/2020/04/17/opinion/remdesivir-coronavirus.html.
Accessed December 10, 2020.
|
|
67
|
Eastman RT, Roth JS, Brimacombe KR,
Simeonov A, Shen M, Patnaik S and Hall MD: Remdesivir: A review of
its discovery and development leading to emergency use
authorization for treatment of COVID-19. ACS Cent Sci. 6:672–683.
2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Eastman RT, Roth JS, Brimacombe KR,
Simeonov A, Shen M, Patnaik S and Hall MD: Correction to
remdesivir: A review of its discovery and development leading to
human clinical trials for treatment of COVID-19. ACS Cent Sci.
6(1009)2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
US Food and Drug Administration (FDA):
Veklury (remdesivir) EUA letter of approval. https://www.fda.gov/media/137564/download. Accessed
December 10, 2020.
|
|
70
|
National Institute for Health and Care
Excellence (NICE): COVID-19 rapid evidence summary: Remdesivir for
treating hospitalised patients with suspected or confirmed
COVID-19. Evidence summary [ES27]. NICE, London, 2020. https://www.nice.org.uk/advice/es27/evidence/evidence-review-pdf-8771329261.
Accessed December 10, 2020.
|
|
71
|
U.S. National Library of Medicine: Study
to Evaluate the Safety, Tolerability, Pharmacokinetics, and
Efficacy of Remdesivir (GS-5734™) in Participants From Birth to
<18 Years of Age With Coronavirus Disease 2019 (COVID-19)
(CARAVAN). ClinicalTrials.gov: NCT04431453.
https://clinicaltrials.gov/ct2/history/NCT04431453.
Accessed December 10, 2020.
|
|
72
|
Chrousos GP and Meduri GU: Critical
COVID-19 disease, homeostasis, and the ‘surprise’ of effective
glucocorticoid therapy. Clin Immunol. 219(108550)2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Katzung BG and Trevor AJ: Basic and
clinical pharmacology, 13th edition. McGraw-Hill, New York, NY,
2015.
|
|
74
|
Tan T, Khoo B, Mills EG, Phylactou M,
Patel B, Eng PC, Thurston L, Muzi B, Meeran K, Prevost AT, et al:
Association between high serum total cortisol concentrations and
mortality from COVID-19. Lancet Diabetes Endocrinol. 8:659–660.
2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Meduri GU and Chrousos GP: General
adaptation in critical illness: Glucocorticoid receptor-alpha
master regulator of homeostatic corrections. Front Endocrinol
(Lausanne). 11(161)2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
World Health Organization (WHO): COVID-19
vaccine tracker and landscape. WHO, Geneva, 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Accessed December 10, 2020.
|
|
77
|
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin
N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey
R, et al: Safety and immunogenicity of two RNA-based Covid-19
vaccine candidates. N Engl J Med. 383:2439–2450. 2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ramasamy MN, Minassian AM, Ewer KJ,
Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B,
Babbage G, et al: Safety and immunogenicity of ChAdOx1 nCoV-19
vaccine administered in a prime-boost regimen in young and old
adults (COV002): A single-blind, randomised, controlled, phase 2/3
trial. Lancet. 396:1979–1993. 2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Anderson EJ, Rouphael NG, Widge AT,
Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens
LJ, Pruijssers AJ, et al: Safety and immunogenicity of SARS-CoV-2
mRNA-1273 vaccine in older adults. N Engl J Med. 383:2427–2438.
2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Polack FP, Thomas SJ, Kitchin N, Absalon
J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED,
Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 383:2603–2615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Voysey M, Clemens SAC, Madhi SA, Weckx LY,
Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE,
et al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
against SARS-CoV-2: An interim analysis of four randomised
controlled trials in Brazil, South Africa, and the UK. Lancet.
397:99–111. 2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Baden LR, El Sahly HM, Essink B, Kotloff
K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
et al: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N
Engl J Med. 384:403–416. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS-CoV-2 infection: Mechanistic insights into current
COVID-19 therapies (Review). Int J Mol Med. 46:467–488.
2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Cascella M, Rajnik M, Aleem A, Dulebohn SC
and Di Napoli R: Features, evaluation, and treatment of coronavirus
(COVID-19). StatPearls, Treasure Island, FL, 2022. https://www.statpearls.com/ArticleLibrary/viewarticle/52171.
Accessed February 22, 2022.
|
|
87
|
Kreier F: Ten billion COVID vaccinations:
World hits new milestone. Nature: Jan 31, 2022 (Epub ahead of
print).
|
|
88
|
NHS England. Rapid Policy Statement:
Interim Clinical Commissioning Policy: Neutralising monoclonal
antibodies or antivirals for non-hospitalised patients with
COVID-19. NHS, London, 2022. https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-neutralising-monoclonal-antibodies-or-antivirals-for-non-hospitalised-patients-with-covid-19/.
Accessed March 9, 2022.
|
|
89
|
Zaky S, Hosny H, Elassal G, Asem N, Baki
AA, Kamal E, Abdelbary A, Said A, Ibrahim H, Taema K, et al:
Clinical evaluation of pregnant women with SARS-COV2 pneumonia: A
real-life study from Egypt. J Egypt Public Health Assoc.
96(29)2021.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Zhang P, Heyman T, Greechan M, Dygulska B,
Al Sayyed F, Narula P and Lederman S: Maternal, neonatal and
placental characteristics of SARS-CoV-2 positive mothers. J Matern
Fetal Neonatal Med: Feb 28, 2021 (Epub ahead of print).
|
|
91
|
Maeda MFY, Brizot ML, Gibelli MABC, Ibidi
SM, Carvalho WB, Hoshida MS, Machado CM, Sabino EC, Oliveira da
Silva LC, Jaenisch T, et al: Vertical transmission of SARS-CoV2
during pregnancy: A high-risk cohort. Prenat Diagn. 41:998–1008.
2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Buonsenso D, Costa S, Giordano L, Priolo
F, Colonna AT, Morini S, Sbarbati M, Pata D, Acampora A, Conti G,
et al: Short- and mid-term multidisciplinary outcomes of newborns
exposed to SARS-CoV-2 in utero or during the perinatal period:
Preliminary findings. Eur J Pediatr: Jan 11, 2022 (Epub ahead of
print).
|
|
93
|
Beesley MA, Davidson JR, Panariello F,
Shibuya S, Scaglioni D, Jones BC, Maksym K, Ogunbiyi O, Sebire NJ,
Cacchiarelli D, et al: COVID-19 and vertical transmission:
Assessing the expression of ACE2/TMPRSS2 in the human fetus and
placenta to assess the risk of SARS-CoV-2 infection. BJOG.
129:256–266. 2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Wang N, Shang J, Jiang S and Du L: Subunit
vaccines against emerging pathogenic human coronaviruses. Front
Microbiol. 11(298)2020.PubMed/NCBI View Article : Google Scholar
|
